Merck And Moderna Diverge On Cancer Vaccine Results
FROM THE WIRE · FINANCE.YAHOO.COM
Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data. Continue Reading
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe diverging shares reflect investor reaction to early cancer vaccine data, which weighs on both companies.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna and Merck shares diverged on Friday.
- 02Investors were digesting the early release of their cancer vaccine data.
- 03The article asks whether the drug still represents a viable treatment.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Merck & Co., Inc.144.92 USD+0.25%today -1.58%Neutral Moderna, Inc.203.89 USD-1.12%today +0.62%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets